DAPSONE (dapsone) by Viatris (2) is 12. Approved for sulfone [epc]. First approved in 2023.
Drug data last refreshed 20h ago
12.1 Mechanism of Action The mechanism of action of dapsone gel in treating acne vulgaris is not known. 12.3 Pharmacokinetics In a pharmacokinetic study, male and female subjects 16 years of age or older with acne vulgaris (N=19) applied 2 grams of dapsone gel, 7.5% to the face, upper chest, upper…
Worked on DAPSONE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sulfone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Dermal Tolerability of Dapsone Gel in Healthy Volunteers
Phototoxicity Test of Dapsone Gel in Healthy Volunteers
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris